Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses

Biotech Cost Trends: Bio-Techne vs. ADMA Biologics

__timestamp	ADMA Biologics, Inc.	Bio-Techne Corporation
Wednesday, January 1, 2014	3742367	106352000
Thursday, January 1, 2015	4311461	144969000
Friday, January 1, 2016	6360761	162364000
Sunday, January 1, 2017	29164321	188462000
Monday, January 1, 2018	42194635	210850000
Tuesday, January 1, 2019	39504238	240515000
Wednesday, January 1, 2020	61291426	255497000
Friday, January 1, 2021	79769341	298182000
Saturday, January 1, 2022	118814535	349103000
Sunday, January 1, 2023	169273000	366887000
Monday, January 1, 2024		389335000

Cracking the code

Unveiling Cost Dynamics in the Biotech Sector

In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for two prominent players: Bio-Techne Corporation and ADMA Biologics, Inc., from 2014 to 2023. Over this period, Bio-Techne consistently outpaced ADMA Biologics, with its cost of revenue peaking at approximately 367% higher in 2023. Notably, Bio-Techne's costs rose steadily, reflecting a robust expansion strategy, while ADMA Biologics experienced a dramatic surge, particularly from 2020 onwards, with a staggering 176% increase by 2023. This sharp rise could indicate strategic investments or scaling operations. However, data for 2024 remains incomplete, leaving room for speculation on future trends. As the biotech industry continues to innovate, these insights offer a glimpse into the financial strategies shaping its future.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025